Durvalumab FDA Approval for Bladder Cancer

Video

Transcript:Evan Yu, MD: Durvalumab is a PD-L1 antibody similar to atezolizumab. I think some of the differences that we’ve seen, if we’re parsing out differences from open-label phase II studies, are that the durvalumab studies have utilized a different antibody to do PD-L1 staining, and they found patients that have a very high percentage of PD-L1 staining and are able to concentrate good responses in those patients. So, that’s one thing to focus on.

I think another interesting thing with durvalumab is that they’re very focused on combination therapies. They have a frontline trial of durvalumab with tremelimumab versus durvalumab alone versus standard chemotherapy. And I think that combination immunotherapy approach could be a very interesting path for the future.

I believe that the future of treatment of metastatic urothelial carcinoma will bring more and more immuno-oncology agents. I think the first thing that we’ll notice is more use earlier in the first-line metastatic disease setting. That’s going to be very, very noticeable. And chemotherapy may be used less in that setting. We might see more later-stage chemotherapy used—or even situations where chemotherapy doesn’t get used. I think it’ll be very important to see the results of some of the front-line trials—a combination of immuno-oncology agents with chemotherapy, combinations of multiple immuno-oncology agents. These things could really change the landscape even more.

I think the other thing we should look forward to is the use of these immuno-oncology agents earlier in the disease state. There are some unmet needs, such as neoadjuvant therapy. We could improve upon what we’re doing right now with cisplatin-based chemotherapy. Adjuvant therapy is a completely unmet need. And non—muscle invasive bladder cancer, when you have BCG-refractory disease, is really an unmet need, and there a lot of patients who would like to preserve their bladder rather than move on to cystectomy. So, I really see the future changing dramatically with all these immuno-oncology agents, and I think there are many other agents to come down the road.

Transcript Edited for Clarity

Related Videos
A panel of 4 experts on bladder cancer
Matthew Milowsky, MD, FASCO, an expert on bladder cancer
Martin H. Voss, MD, an expert on renal cell carcinoma
Laurence Albigès, MD, PhD, an expert on renal cell carcinoma
Nikhil A. Gopal, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer